When was Perfuse Therapeutics founded?

Perfuse Therapeutics was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is Perfuse Therapeutics located?

Perfuse Therapeutics is headquartered in San Francisco, United States.

How many employees does Perfuse Therapeutics have?

As of Sep 30, 2026, the latest employee count at Perfuse Therapeutics is 8.

Is Perfuse Therapeutics a funded company?

Perfuse Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Jul 2020.

When was the latest funding round of Perfuse Therapeutics?

Perfuse Therapeutics' latest funding was a $***** Series A round on Jul 2020, with participation from 1 investor.

Where does Perfuse Therapeutics rank among its competitors?

Perfuse Therapeutics ranks 1st amongst 76 active competitors, of which 10 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was IRIDEX, which secured $10M in Mar, 2025.

Who are the top competitors of Perfuse Therapeutics?

Perfuse Therapeutics' top competitors include IRIDEX, MicroSurgical Technology and Appasamy Associates. Among them, IRIDEX secured the most recent funding round in March, 2025.

Perfuse Therapeutics - 2026 Company Profile, Funding & Competitors

Perfuse Therapeutics is an acquired company based in San Francisco (United States), founded in 2018. It operates as a Developer of therapies to treat eye disorders. Perfuse Therapeutics has raised an undisclosed amount in funding from Access Industries. The company has 76 active competitors, including 10 funded and 18 that have exited. Its top competitors include companies like IRIDEX, MicroSurgical Technology and Appasamy Associates.

Company Details

Perfuse Therapeutics is a developer of therapies to eye disorders such as glaucoma. The company has developed a novel technology to improve retinal perfusion for the treatment of retinal diseases. The company is using the mechanism for the treatment of glaucoma.

Website: perfusetherapeutics.com
Email ID: *****@perfusetherapeutics.com

Key Metrics

Founded Year

2018

Location

San Francisco, United States

Stage

Acquired

Latest Funding Round

Series A, Jul 2020, $*****

Investors

Access Industries & 4 more

Ranked

1^st among 76 active competitors

Employee Count

8 as on Sep 30, 2026

Similar Companies

IRIDEX & 86 more

Exit Details

Acquired by Bayer (May 06, 2026)

View Perfuse Therapeutics' full profile

Perfuse Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Perfuse Therapeutics, Inc CIN: 833240662 , United States, Active		-	-	-

Perfuse Therapeutics got acquired by Bayer on May 06, 2026.

Click here to take a look at Perfuse Therapeutics's acquisition in detail

Perfuse Therapeutics has raised funding over 1 round. Its latest funding round was a Series A round on Jul 2020 for $*****. 1 investor participated in its latest round. Perfuse Therapeutics has 5 institutional investors.

Here is the list of recent funding rounds of Perfuse Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 2020	8877508	Series A	5528584	9525212	4425683	2969739

Access funding benchmarks and valuations. Sign up today!

View details of Perfuse Therapeutics's funding rounds and investors

Perfuse Therapeutics' employee count trend

Perfuse Therapeutics has 8 employees as of Sep 26. Here is Perfuse Therapeutics's employee count trend over the years:

Employee count trend for Perfuse Therapeutics

Uncover Perfuse Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Perfuse Therapeutics include IRIDEX, MicroSurgical Technology and Appasamy Associates. Here is the list of Top 10 competitors of Perfuse Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Perfuse Therapeutics 2018, San Francisco (United States), Acquired	Developer of therapies to treat eye disorders	-	Access Industries, Orbimed & 3 others	49/100
2nd	IRIDEX 1989, Mountain View (United States), Public	Manufacturer of ophthalmic laser systems and surgical instruments for eyes	-	Incubic, Technology Partners & 1 others	48/100
3rd	MicroSurgical Technology 1976, Redmond (United States), Acquired	Develops a portfolio of Surgical tools for Ophthalmic surgeries	-	-	47/100
4th	Appasamy Associates 1978, Chennai (India), Acquired	Developer of ophthalmic instruments and pharmaceutical products	-	BIRAC	46/100
5th	Dopavision 2017, Berlin (Germany), Series A	Developer of a digital therapeutic for myopia	$17.4M	Boehringer Ingelheim Venture Fund, Seventure Partners ... & 9 others	45/100
6th	Oertli Instrumente 1955, Berneck (Switzerland), Unfunded	Developer of ophthalmology medical device	-	-	44/100
7th	Keeler 1917, Windsor (United Kingdom), Unfunded	A portfolio of ophthalmic devices	-	-	44/100
8th	Lalji International 2018, Ahmedabad (India), Unfunded	Manufacturer of disposable medical drapes and surgical gowns. The company produces a variety of products for various medical applications, including ophthalmology, gynecology, and general surgery. These products are designed for single-use and contribute to maintaining a sterile environment during procedures. The manufacturing process emphasizes quality control to ensure the safety and efficacy of the products. The company's offerings also include hospital beds and related furniture.	-	-	42/100
9th	Lamellar 2007, Glasgow (United Kingdom), Series C	Develops patented medical devices and pharmaceuticals based on mimetics of extra-alveolar lamellar bodies	$18.4M	Hambro Perks, Invesco & 4 others	42/100
10th	Ziemer Ophthalmology 2005, Basel (Switzerland), Series B	Portfolio of devices for refractive and corneal surgery	$17.4M	BV Partners, HBM Partners & 1 others	40/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Perfuse Therapeutics's competitors? Click here to see the top ones

Perfuse Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Perfuse Therapeutics's sector:

Free

Ophthalmology - Sector Report

Edition: September, 2026 (68 Pages)

View all reports related to Perfuse Therapeutics

Media has covered Perfuse Therapeutics for a total of 9 events in the last 1 year, 3 of them have been about company updates and 1 about partnerships.